From: Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial
Group
13 Weeks n (%)
26 Weeks n (%)
Synvisc-One
17 (53)
19 (59)
Hydros
21 (66)
22 (69)
Hydros-TA
24 (71)
22 (65)